156 related articles for article (PubMed ID: 22449782)
1. TLR ligand-peptide conjugate vaccines: toward clinical application.
Zom GG; Khan S; Filippov DV; Ossendorp F
Adv Immunol; 2012; 114():177-201. PubMed ID: 22449782
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
[TBL] [Abstract][Full Text] [Related]
3. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients.
Quakkelaar ED; Melief CJ
Adv Immunol; 2012; 114():77-106. PubMed ID: 22449779
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
5. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
Khan S; Weterings JJ; Britten CM; de Jong AR; Graafland D; Melief CJ; van der Burg SH; van der Marel G; Overkleeft HS; Filippov DV; Ossendorp F
Mol Immunol; 2009 Mar; 46(6):1084-91. PubMed ID: 19027958
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor ligands energize peptide vaccines through multiple paths.
Celis E
Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses.
Garaude J; Kent A; van Rooijen N; Blander JM
Sci Transl Med; 2012 Feb; 4(120):120ra16. PubMed ID: 22323829
[TBL] [Abstract][Full Text] [Related]
8. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
9. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
Welters MJ; Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
Vaccine; 2007 Feb; 25(8):1379-89. PubMed ID: 17123670
[TBL] [Abstract][Full Text] [Related]
10. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
Melief CJ; van der Burg SH
Nat Rev Cancer; 2008 May; 8(5):351-60. PubMed ID: 18418403
[TBL] [Abstract][Full Text] [Related]
13. Self-Adjuvanting Cancer Vaccines from Conjugation-Ready Lipid A Analogues and Synthetic Long Peptides.
Reintjens NRM; Tondini E; de Jong AR; Meeuwenoord NJ; Chiodo F; Peterse E; Overkleeft HS; Filippov DV; van der Marel GA; Ossendorp F; Codée JDC
J Med Chem; 2020 Oct; 63(20):11691-11706. PubMed ID: 32960056
[TBL] [Abstract][Full Text] [Related]
14. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
15. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
[TBL] [Abstract][Full Text] [Related]
16. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
17. [Dendrite cell-based cancer vaccines--clinical application].
Svane IM; Berntsen A; Trepiakas R; Pedersen AE
Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
19. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
20. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY; Wang RF
Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]